

BACIL PHARMA LIMITED

Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099
Email Id: bacilpha@yahoo.com, CIN: L24200MH1987PLC043427,
Tel: 22618452/22661541, Tel/Fax: 22618327

Date: November 13, 2025

To,
The Manager,
Listing Department,
BSE Limited
P. J. Towers, Dalal Street,
Mumbai – 400001
Scrip Code: 524516

Sub: Outcome of the Board Meeting held on Thursday, November 13, 2025
Ref: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we wish to inform you that the Meeting of the Board of Directors of Shree Krishna Infrastructure Limited was held on Thursday, November 13, 2025 at the Registered Office of the Company, wherein the Board has, inter alia, considered and approved the following:

1. Approved the Unaudited Financial Results of the Company for the half year and quarter ended September 30, 2025, along with the Limited Review Report issued by the Statutory Auditors of the Company.

The meeting of the Board of Directors commenced at 06:00P.M. and concluded at 07:30 P.M.

The Unaudited Financial Results and Limited Review Report will be submitted separately in the prescribed format as per SEBI LODR Regulations.

Kindly take the above on your record and acknowledge the receipt.

Thanking you,

For Bacil Pharma Limited

Chaitali Kalpataru Shah
Director
Din: 11167778

BACIL PHARMA LIMITED

{CIN : L24200MH1987PLC043427}

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER,2025

(₹ in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended
		30-09-2025	30-06-2025	30-09-2024	31-03-2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-
	Other income	5.49	100.25	56.04	66.14
	Total revenue	5.49	100.25	56.04	66.14
2	Expenses				
	Employee benefits expense	0.63	2.95	3.91	13.84
	Depreciation and amortization expense	-	-	0.04	0.07
	Other expenses	3.02	7.94	3.34	11.47
	Total expenses	3.65	10.89	7.29	25.38
	Profit / (Loss) from ordinary activities before tax	1.84	89.36	48.74	40.76
3	Tax expense:				
	Current tax	(0.46)	(22.49)	-	-
	Deferred tax	-	-	(0.34)	(0.34)
4	Profit/(Loss) from ordinary activities after tax	1.38	66.87	48.40	40.42
5	Other Comprehensive Income (OCI)				
	<u>Item that will not be reclassified to profit or loss</u>				
	Gain/(Loss) on recognised on fair valuation of Financial Assets	(1.86)	8.55	(29.78)	(0.49)
	Income tax relating to these items	1.40	(2.22)	7.74	0.13
	Total Other Comprehensive Income (OCI)	(0.46)	6.33	(22.04)	(0.36)
	Profit/(Loss) for the Period	0.92	73.20	26.37	40.06
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,397.03	1,397.03	589.00	1,397.02
6	Earning Per Share (EPS) (Not annualised)				
	(1) Basic	0.01	0.48	0.82	0.64
	(2) Diluted	0.01	0.48	0.82	0.64

Notes:

- The Above Financial Results were reviewed by the audit committee of the board on _____ and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed on unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- Figures for the corresponding quarter ended i.e. 31st March 2025 in the previous year as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the relevant financial year.
- The Company has single business segment therefore in the context of Ind As 108, disclosure of segment information is not applicable.
- Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.

For and on behalf of the Board

Bacil Pharma Limited

Chaitali Kalpataru Shah

(Director)

DIN: 10289995

BACIL PHARMA LIMITED

CIN :L24200MH1987PLC043427

Regd. Off.: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099

Email: bacilpha@yahoo.com

Balance Sheet as at 30th September,2025

(Rupees in Lacs)

Particulars	Note No.	As at 30th September,2025	As at 31st March, 2025
I. ASSETS			
1 Non-current assets			
Property Plant and Equipment	3	0.00	0.00
<u>Assets Classified as held for sale</u>			
Property Plant and Equipments		0.00	0.00
Financial Assets			
(a) Investments	4	2253.66	2135.66
(b) Loans	5	85.89	128.26
Deferred tax assets (net)	6	5.36	5.36
2 Current assets			
Financial Assets			
(a) Investments			-
(b) Trade receivables		4.72	-
(c) Cash and cash equivalents	7	159.38	285.73
Other current assets	8	149.50	5.02
Total		2658.5079	2560.0218
II. EQUITY AND LIABILITIES			
1 Equity			
Equity Share capital	9	1397.0150	1397.0150
Other Equity	10	1238.0227	1146.1159
2 Non-current liabilities			
Financial Liabilities			-
Deferred tax liabilities			-
3 Current liabilities			
Financial Liabilities			
(a) Borrowings	11	0	16.3930

(b) Trade Payables	12		
Total outstanding due of			
(A) Micro enterprises and small enterprises			
(B) Creditors other than micro enterprises and small enterprises		5.29869	0.4117
(c) Other Financial Liabilities			
Other current liabilities	13	18.0240	0.0861
Provisions	14	0.1475	0.0000
Total		2658.5079	2560.0218
<u>Summary of Significant Accounting Policies</u>			
See Other notes to Accounts			
Notes referred to above form part of Balance Sheet			
For and on behalf of the Board			
Bacil Pharma Limited			
Chaitali Kalpataru Shah			
(Director)			
DIN: 10289995			

BACIL PHARMA LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 30TH SEPTEMBER, 2025

(Amount in LAKH)

Particulars	Year ended 30.09.2025	Year ended 31.03.2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (Loss) /profit before tax	1.84	40.76
<u>Adjustments for</u>		
Depreciation	-	0.07
Loss on sale of Fixed Asset	0	0.55
Interest & Dividend Income	0	-2.94
Operating profit before working capital changes	1.84	38.44
Working Capital adjustments :-		
Increase/(Decrease) in Trade and Other Payables	4.89	0.05
Increase/(Decrease) in Borrowings	-16.39	6.55
Increase/(Decrease) in Provisions	0.15	0
Increase/(Decrease) in Other Financial Liabilities	-1.84	-0.85
Increase/(Decrease) in Other Current Liabilities	17.94	-0.15
(Increase)/Decrease in Trade Receivable	-4.72	0
(Increase)/Decrease in Other Current Assets	-144.48	-3.96
Cash generated from /(used in) operations	-142.62	40.08
Direct taxes paid (Net of Refunds)		
Net cash (used in)/ from generated from operating activities		
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant & Equipment	0	0
Proceeds Purchase/Sale of Investments	0	30.73
Interest & Dividend Income	0	2.94
Increase in Investment	-118.00	0
Decrease in Loans	42.37	
Net cash (used in)/ from generated from investing activities	-75.63	33.67
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase/(Decrease) of Unsecured Loan	0	-68.17
Proceeds from Preferential Allotment of Shares	0	276
Increase/(Decrease) of other equity	91.91	0

Net cash (used in)/ from generated from financing activities	91.90678	207.83
D. Net Increase/Decrease in cash and cash equivalents (A+B+C)	-126.35	281.58
Cash and Cash equivalents at the beginning of the year	285.73	4.15
Cash and Cash equivalents at the end of the year	159.38	285.73
<p>Notes referred to above form part of Balance Sheet</p> <p>For and on behalf of the Board Bacil Pharma Limited</p> <p>Chaitali Kalpataru Shah Director DIN: 10289995</p>		



**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

Independent Auditor's Review Report on the Quarter Ended 30th September, 2025
Unaudited Financial Results of the Company Pursuant to Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors
BACIL PHARMA LIMITED

1. We have reviewed the accompanying statement of unaudited financial results of BACIL PHARMA LIMITED (the "Company") for the Quarter ended September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "listing Regulations").
2. Company's Board of Directors responsibility of the Company's Management and Approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of the Interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The information and data contained in this report are based solely on the documents, explanations, and representations provided by the management of the entity. We have not independently verified the correctness or completeness of such information and records, and our verification has been limited to the extent of information made available to us during the course of our review.





**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

5. Emphasis of Matter

- (i) The Company has raised funds through preferential allotment. In the absence of adequate documentation and explanations from the management, we are unable to verify their application and end use. Due to lack of complete information and confirmations from management, we are unable to determine whether certain transactions during the quarter are with related parties and if so, whether they are at arm's length. In the absence of sufficient documentation regarding advances/deposits given during the quarter, we are unable to comment on their nature, purpose, recoverability and compliance with applicable provisions.
- (ii) This report is prepared for the exclusive use of the entity and is based on a limited review; it should not be considered as an audit or certification of factual accuracy. We do not assume responsibility to update or revise the report for events occurring after the date of issuance. Nothing contained herein should be construed as an assurance of future performance, compliance, or financial position of the entity. Our responsibility is restricted to the reporting requirements as per the scope of engagement agreed with management and in accordance with the Standards on Quality Control (SQC 1) and relevant Guidance Notes issued by ICAI. This report does not, in any manner, express an audit opinion under the Companies Act, 2013 or under any other statute. The management is responsible for compliance with applicable laws and maintenance of adequate internal controls.
- (iii) During the course of our review, it was observed that the Company has not complied with certain statutory requirements under the Goods and Services Tax Act, 2017 and the Income-tax Act, 1961 relating to timely





SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES

CHARTERED ACCOUNTANTS

CA SARANG CHAVAN

+91 9974 62 3154

chavansarang1@gmail.com

deposit and filing of GST returns and TDS statements. Consequently, interest, penalties, and other liabilities, if any, arising therefrom have not been ascertained and provided for in the books of accounts. In our opinion, this constitutes a non-compliance with statutory provisions which may have a material impact on the financial statements. The above observation is based solely on information and explanations provided by management and our limited review procedures. We have not carried out an audit, and accordingly, we do not express an audit opinion.

- (iv) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (listing obligations and Disclosure Requirements) Regulations, 2015 read with the Circular, Including the Manner in which it is to be disclosed or that it contains any material misstatement.
- (v) We have not been provided any data regarding debtors and creditors confirmation from management and hence we have relied on management declaration and representation made by them.
- (vi) With regard to investments and deposits made in books of accounts, we have not been provided any data from management and hence we have relied on management declaration and representation made by them..






**SARANG SHIVAJIRAO CHAVAN
AND ASSOCIATES**
CHARTERED ACCOUNTANTS

CA SARANG CHAVAN
+91 9974 62 3154
chavansarang1@gmail.com

- (vii) We do not express an opinion on the Statement of the Company. Because of the significance of the matters described in the Basis for Disclaimer of Opinion section of our review report, we have not been able to obtain sufficient and appropriate audit evidence to provide a basis for our opinion on the Statement.

FOR
SARANG SHIVAJIRAO CHAVAN AND ASSOCIATES
CHARTERED ACCOUNTANTS
FRN: 159649W


CA SARANG CHAVAN
(PROPRIETOR)
M.NO.142576
UDIN: 25142576BMIUUR4982
Date: 13/11/2025
Place: Ahmedabad

